Previous 10 | Next 10 |
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 13:03:55 ET The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with this event. For further details see: bridgebio shares phase 2 data for infigratinib in achondroplasia
2023-03-06 12:22:36 ET Shares of BridgeBio Pharma (NASDAQ: BBIO) were skyrocketing 61.2% higher as of 11:55 a.m. ET on Monday. The huge gain came after the company announced positive results from a patient cohort in a phase 2 clinical study evaluating infigratinib in treating childr...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 08:21:43 ET BridgeBio Pharma ( NASDAQ: BBIO ) jumped ~55% pre-market Monday after announcing Phase 2 data for infigratinib, which is an investigational therapy for children with achondroplasia, the most common cause of disproportionate short stature. Cohort 5,...
- In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022 ) for the first 10 children with at least six months of follow-up in Cohort 5. The two remaining children who have not yet...
PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 ...
The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: BridgeBio Pharma, Inc. 2023 Q1 - Results - Earnings Call Presentation
BridgeBio Pharma press release ( NASDAQ: BBIO ): Q4 GAAP EPS of -$0.92 misses by $0.07 . Revenue of $1.87M (-85.5% Y/Y) misses by $3.05M . Cash, cash equivalents, marketable securities and restricted cash (current), totaled $466.2 million as of December 31, 2022, ...
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigrat...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...